Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372109 | 0.93 | MET (0.53) | METFLT3IRAK4KDREGFR | |
| SCHEMBL3857019 | 0.92 | MET (0.53) | METFLT3IRAK4AXLKDR | |
| SCHEMBL15103894 | 0.91 | MET (0.54) | METFLT3IRAK4KDR | |
| SCHEMBL3976731 | 0.91 | MET (0.56) | METFLT3IRAK4AXLKDR | |
| SCHEMBL3832583 | 0.91 | MET (0.57) | METFLT3IRAK4KDR | |
| SCHEMBL3829238 | 0.91 | MET (0.52) | METFLT3IRAK4AXLKDR | |
| SCHEMBL15520757 | 0.91 | MET (0.52) | METFLT3IRAK4AXLKDR | |
| SCHEMBL2202519 | 0.90 | MET (0.51) | METFLT3IRAK4AXLKDR | |
| SCHEMBL15263369 | 0.90 | MET (0.53) | METFLT3IRAK4AXLKDR | |
| SCHEMBL3832694 | 0.90 | MET (0.53) | METFLT3IRAK4AXLKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476298-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MET 2/4885FLT3 7/4885IRAK4 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.